Arming NK cells with enhanced antitumor activity

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Oberoi, Pranav ^a   Wels, Winfried S ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Chimeric antigen receptor; Granzyme B; NK cells

Indexed keywords

CD3 ANTIGEN; CHIMERIC PROTEIN; DIPEPTIDYL PEPTIDASE I; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANZYME B; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN; PERFORIN; SIGNAL PEPTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA;

ADOPTIVE TRANSFER; AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; DEGRANULATION; ENZYME ACTIVATION; ENZYME RELEASE; GENE EXPRESSION; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR;

EID: 84885712333     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25220     Document Type: Article

References (10)

1. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008; 8:713-25; PMID:19172692; http://dx.doi. org/10.1038/nri2381
2. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol- 031210-101324
3. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi.org/10.1016/S0140- 6736(00)03231-1
4. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12:239-52; PMID:22437937; http://dx.doi.org/10.1038/nri3174
5. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008; 9:486-94; PMID:18425105; http:// dx.doi.org/10.1038/ni1580
6. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killercell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100:1265-73; PMID:12149207
7. Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012; 61:1451-61; PMID:22310931; http://dx.doi.org/10.1007/s00262-012-1212-x
8. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J Innate Immun 2011; 3:355-64; PMID:21502747; http://dx.doi. org/10.1159/000325465
9. Oberoi P, Jabulowsky RA, Bähr-Mahmud H, Wels WS. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PLoS One 2013; 8:e61267; PMID:23573299; http://dx.doi.org/10.1371/journal. pone.0061267
10. Oberoi P, Jabulowsky RA, Wels WS. Selective induction of cancer cell death by targeted granzyme B. Antibodies 2013; 2:130-51; http://dx.doi.org/10.3390/ antib2010130